Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [ 177 Lu]Lu-DOTA-TATE or [ 177 Lu]Lu-DOTA-TATE and [ 90 Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center.

Simple Summary: Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells, with increasing global incidence and prevalence. Radioligand therapy (RLT) with beta-emitting radioisotopes is an effective and relatively safe treatment, surpassing other pharmacotherapies in tolerability. A study by Poland's top radioisotope-treatment center analyzed 167 patients over 66 months, administering 479 RLT radioisotope doses. Non-functioning G2 NENs with a mean Ki-67 of 6.05% were predominant, often originating in the pancreas. Post-RLT disease stabilization occurred in 69.46%, partial regression in 20.36%, complete regression in 0.60%, and progression in 9.58% of patients. Long-term follow-up (median 29.8 months) revealed stabilization in 55.56% of patients, progression in 26.85% of patients, and a 17.59% mortality rate. Median PFS and OS were 29.3 and 34.0 months, respectively. Thus, the study showed that RLT lead to disease stabilization in over half of the patients with progressive disease in long-term observation. Poland's coordinated NEN treatment in high-reference centers ensures consistent patient care. Neuroendocrine neoplasms (NENs) are a group of neoplasms arising from neuroendocrine cells. The worldwide incidence and prevalence of the NENs are estimated to be 6/100,000 and 35/100,000, respectively. Those numbers are increasing every decade, requiring higher and higher diagnosis and treatment costs. Radioligand therapy (RLT) using beta-emitting radioisotopes is an efficient and relatively safe method of treatment, typically used as a second-line treatment. RLT tolerability is higher than other available pharmacotherapies (chemotherapy or tyrosine kinase inhibitors). Recent studies show an increase in overall survival among patients treated with RLT. The present study aimed to learn the epidemiology of NENs in Poland and assess the effectiveness of RLT in a high-reference center. A prospective analysis of 167 patients treated with RLT in one of Poland's highest-reference NEN centers was performed. The analysis covered 66 months of observation (1 December 2017–30 May 2023), during which 479 RLT single administrations of radioisotope were given. The standard procedure was to give four courses of [177Lu]Lu-DOTA-TATE alone, or tandem therapy—[177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE. Grading analysis showed that most patients had non-functioning G2 NEN with a mean Ki-67 of 6.05% (SD ± 6.41). The most common primary tumor location was the pancreas. Over two-thirds of patients did undergo surgery due to primary tumors or distant metastases. The majority of patients were using lanreotide as a chronically injected somatostatin analog. Median progression-free survival (PFS) on somatostatin analogs was 21.0 (IQR = 29.0) months. Directly after the last course of RLT, disease stabilization was noted in 69.46% of patients, partial regression was noted in 20.36% of patients, complete regression was noted in 0.60% of patients, and progression was noted in 9.58% of patients. In long-term follow-up, the median observation time among patients who underwent four treatment cycles (n = 108) was 29.8 (IQR = 23.9) months. Stabilization of the disease was observed in 55.56% of the patients and progression was observed in 26.85% of the patients, while 17.59% of patients died. Median PFS was 29.3 (IQR 23.9), and the median OS was 34.0 months (IQR 16.0). The mean age of NEN diagnosis is the sixth decade of life. It takes almost three years from NEN diagnosis to the start of RLT. In long-term observation, RLT leads to disease stabilization in over half of the patients with progressive disease. No differences in PFS or OS depend on the radioisotope used for RLT. In Poland, organized coordination of NEN treatment in high-reference centers ensures the continuity of patient care. [ABSTRACT FROM AUTHOR]